3 Biotech Stocks That Could More Than Triple if Their Trials Succeed

Overall, the consensus for Astria stock is a “Strong Buy.” Among the 10 analysts covering the company, nine give it a “Strong Buy” rating, and one suggests holding. The average price target of $29.89 indicates potential 253.7% upside from current levels. Meanwhile, the high price target of $49 implies the stock could surge by as much as 479.8% over the next year.In the second quarter, research and development expenses rose to $25.9 million, reflecting higher costs related to Navenibart’s Phase 3 trial and o ...